Results 81 to 90 of about 14,442 (179)

Persistence of Antibodies against Measles, Mumps, and Rubella after the Two-Dose MMR Vaccination: A 7-Year Follow-Up Study

Vaccines
In 2014, the Expanded Program on Immunization of Thailand changed the timing of the second dose of the measles–mumps–rubella (MMR) vaccine from 4–6 years to 2.5 years, while maintaining the first dose at 9 months of age.
Nasiri Sarawanangkoor, Nasamon Wanlapakorn, Donchida Srimuan, Thaksaporn Thatsanathorn, Thanunrat Thongmee, Yong Poovorawan   +5 more
doaj   +1 more source

Intralesional Immunotherapy with Measles-Mumps-Rubella Vaccine for Recalcitrant Facial Warts: A Report of Two Cases. [PDF]

Oman Med J, 2022
Al-Qassabi AM, Al Kindi A.
europepmc   +1 more source

MMR (measles-mumps-rubella) vaccine [PDF]

Paediatrics & Child Health, 2001
openaire   +2 more sources

Characteristics of the epidemic process of measles, rubella and mumps in Moscow and assessment of their seroprevalence at the present stage

Вопросы вирусологии
Introduction. The problem of vaccine-preventable infections requires assessing the state of herd immunity through serological monitoring. The aim. To study the epidemiological features of measles, rubella and mumps and to estimate their seroprevalence
Yana V. Simakova, Vladimir A. Gushchin, Tatiana A. Semenenko, Daria A. Ogarkova, Denis A. Kleymenov, Anna V. Nozdracheva, Victor A. Manuylov, Artem P. Tkachuk, Alexander L. Gintsburg   +8 more
doaj   +1 more source

The Influence of Sex, Body Mass Index, and Age on Cellular and Humoral Immune Responses Against Measles After a Third Dose of Measles-Mumps-Rubella Vaccine. [PDF]

J Infect Dis, 2022
Quach HQ, Chen J, Monroe JM, Ratishvili T, Warner ND, Grill DE, Haralambieva IH, Ovsyannikova IG, Poland GA, Kennedy RB.   +9 more
europepmc   +1 more source

A cross-sectional study of seroprevalence in Armenia, 2025: measles, mumps, rubella, and diphtheria

Frontiers in Public Health
IntroductionPrevention and control of vaccine-preventable infections is a key component of maintaining public health, and the overall state of immunity is the determining factor.Objective of the studyTo study herd immunity of the Armenian population to ...
A. Y. Popova, V. S. Smirnov, S. A. Egorova, S. A. Atoyan, S. A. Atoyan, L. V. Buts, A. M. Milichkina, G. G. Melik-Andreasyan, G. G. Melik-Andreasyan, O. B. Zhimbaeva, S. S. Grigoryan, S. S. Grigoryan, Z. G. Grigoryan, E. M. Danilova, E. S. Ramsay, V. G. Drobyshevskaya, D. A. Starkova, K. A. Frolova, N. N. Zotkin, T. V. Arbuzova, L. V. Suzhaeva, A. V. Svarval, V. A. Ivanov, O. V. Kotsar, V. Y. Smolensky, A. A. Totolian   +25 more
doaj   +1 more source

Number of doses of Measles-Mumps-Rubella vaccine applied in Brazil before and during the COVID-19 pandemic. [PDF]

BMC Infect Dis, 2021
da Silva TMR, de Sá ACMGN, Vieira EWR, Prates EJS, Beinner MA, Matozinhos FP.   +5 more
europepmc   +1 more source

Measles Virus Neutralizing Antibody Response and Durability Two Years after One or Two Doses of Measles-Mumps-Rubella Vaccine among Young Seronegative Healthcare Workers. [PDF]

Vaccines (Basel), 2022
Jang B, Kim HW, Kim HS, Park JY, Seo H, Kim YK.   +5 more
europepmc   +1 more source

Influence of measles-mumps-rubella vaccine series initiation and completion on influenza vaccination among adolescents. [PDF]

Int J Pediatr Adolesc Med, 2022
Beeninga FT, Cortright L, Buckman C, Tumin D, Syed S.   +4 more
europepmc   +1 more source

Reply to Özdemir, "Measles-Mumps-Rubella Vaccine and COVID-19 Relationship". [PDF]

mBio, 2020
Fidel PL, Noverr MC.
europepmc   +1 more source